Page last updated: 2024-08-21

pyrazines and busulfan

pyrazines has been researched along with busulfan in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Drize, N; Nifontova, I; Petrova, T; Svinareva, D	1
Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T	1
Akpek, G; Armstrong, E; Elekes, A; Freytes, CO; Kato, K; Patil, S; Ratanatharathorn, V; Reece, DE; Rodriguez, TE; Sahovic, E; Shaughnessy, PJ; Smith, A; Solomon, SR; Stadtmauer, EA; Toro, JJ; Tricot, GJ; White, DJ; Yeh, RF; Yu, LH; Zhao, C	1

Trials

2 trial(s) available for pyrazines and busulfan

Article	Year
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leukemia & lymphoma, 2011, Volume: 52, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2011
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Pyrazines; Survival Rate; Transplantation Conditioning	2014

Article

Year

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

Leukemia & lymphoma, 2011, Volume: 52, Issue:8

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2011

Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Pyrazines; Survival Rate; Transplantation Conditioning

2014

Other Studies

1 other study(ies) available for pyrazines and busulfan

Article	Year
Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases. Acta haematologica, 2008, Volume: 119, Issue:2 Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Busulfan; Cyclophosphamide; Cytarabine; Female; Fibroblasts; Mesenchymal Stem Cells; Methotrexate; Mice; Mice, Inbred Strains; Pyrazines; Stromal Cells	2008

Article

Year

Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases.

Acta haematologica, 2008, Volume: 119, Issue:2

Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Busulfan; Cyclophosphamide; Cytarabine; Female; Fibroblasts; Mesenchymal Stem Cells; Methotrexate; Mice; Mice, Inbred Strains; Pyrazines; Stromal Cells

2008